110 related articles for article (PubMed ID: 38546787)
1. Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer.
Goto Y; Kurozumi A; Arai T; Nohata N; Kojima S; Okato A; Kato M; Yamazaki K; Ishida Y; Naya Y; Ichikawa T; Seki N
Br J Cancer; 2017 Jul; 117(3):409-420. PubMed ID: 28641312
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.
Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X
J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856
[TBL] [Abstract][Full Text] [Related]
3. DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer.
Guo S; Miao M; Wu Y; Pan D; Wu Q; Kang Z; Zeng J; Zhong G; Liu C; Wang J
Oncogene; 2024 May; 43(19):1399-1410. PubMed ID: 38480915
[TBL] [Abstract][Full Text] [Related]
4. Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion.
Wang H; Zhou Y; Chu C; Xiao J; Zheng S; Korpal M; Korn JM; Penaloza T; Drake RR; Gan W; Gao X
Mol Cancer Res; 2023 Dec; 21(12):1317-1328. PubMed ID: 37606694
[TBL] [Abstract][Full Text] [Related]
5. Mediator kinase module proteins, genetic alterations and expression of super-enhancer regulated genes in colorectal cancer.
Voutsadakis IA
Pharmacol Rep; 2024 Jun; 76(3):535-556. PubMed ID: 38602606
[TBL] [Abstract][Full Text] [Related]
6. Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone.
Fradet A; Bouchet M; Delliaux C; Gervais M; Kan C; Benetollo C; Pantano F; Vargas G; Bouazza L; Croset M; Bala Y; Leroy X; Rosol TJ; Rieusset J; Bellahcène A; Castronovo V; Aubin JE; Clézardin P; Duterque-Coquillaud M; Bonnelye E
Oncotarget; 2016 Nov; 7(47):77071-77086. PubMed ID: 27776343
[TBL] [Abstract][Full Text] [Related]
7. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E
Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002
[TBL] [Abstract][Full Text] [Related]
8. Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6.
Choudhury AD; Schinzel AC; Cotter MB; Lis RT; Labella K; Lock YJ; Izzo F; Guney I; Bowden M; Li YY; Patel J; Hartman E; Carr SA; Schenone M; Jaffe JD; Kantoff PW; Hammerman PS; Hahn WC
Cancer Res; 2017 Feb; 77(3):753-765. PubMed ID: 27899381
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer.
Chung S; Tamura K; Furihata M; Uemura M; Daigo Y; Nasu Y; Miki T; Shuin T; Fujioka T; Nakamura Y; Nakagawa H
Cancer Sci; 2009 Nov; 100(11):2109-14. PubMed ID: 19664042
[TBL] [Abstract][Full Text] [Related]
10. Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome.
Cozzolino K; Sanford L; Hunter S; Molison K; Erickson B; Jones T; Courvan MCS; Ajit D; Galbraith MD; Espinosa JM; Bentley DL; Allen MA; Dowell RD; Taatjes DJ
bioRxiv; 2024 May; ():. PubMed ID: 37461585
[TBL] [Abstract][Full Text] [Related]
11. CDK12-inactivation-induced MYC signaling causes dependency on the splicing kinase SRPK1.
Liang J; Gondane A; Itkonen HM
Mol Oncol; 2024 May; ():. PubMed ID: 38775167
[TBL] [Abstract][Full Text] [Related]
12. Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer.
Pan H; Jansson KH; Beshiri ML; Yin J; Fang L; Agarwal S; Nguyen H; Corey E; Zhang Y; Liu J; Fan H; Lin H; Kelly K
Oncotarget; 2017 Sep; 8(44):77181-77194. PubMed ID: 29100379
[TBL] [Abstract][Full Text] [Related]
13. Mediator kinase inhibition reverses castration resistance of advanced prostate cancer.
Li J; Hilimire TA; Liu Y; Wang L; Liang J; Gyorffy B; Sikirzhytski V; Ji H; Zhang L; Cheng C; Ding X; Kerr KR; Dowling CE; Chumanevich AA; Mack ZT; Schools GP; Lim CU; Ellis L; Zi X; Porter DC; Broude EV; McInnes C; Wilding G; Lilly MB; Roninson IB; Chen M
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38546787
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
15. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract][Full Text] [Related]
16. CDK8 and CDK19: positive regulators of signal-induced transcription and negative regulators of Mediator complex proteins.
Chen M; Li J; Zhang L; Wang L; Cheng C; Ji H; Altilia S; Ding X; Cai G; Altomare D; Shtutman M; Byrum SD; Mackintosh SG; Feoktistov A; Soshnikova N; Mogila VA; Tatarskiy V; Erokhin M; Chetverina D; Prawira A; Ni Y; Urban S; McInnes C; Broude EV; Roninson IB
Nucleic Acids Res; 2023 Aug; 51(14):7288-7313. PubMed ID: 37378433
[TBL] [Abstract][Full Text] [Related]
17. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
18. Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
Denmeade SR; Sena LA; Wang H; Antonarakis ES; Markowski MC
Oncologist; 2023 Jun; 28(6):465-473. PubMed ID: 37027449
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
